SHANGHAI, CHINA--(MARKET WIRE)--Sep 4, 2007 -- Sinobiomed Inc. ("the Company") (OTC BB:SOBM.OB - News) is pleased to announce that its 82% owned subsidiary, Shanghai Wanxing Bio-pharmaceuticals Co., Ltd. (Shanghai Wanxing), has completed a two-day recruiting and product training conference for sales agents for its patented recombinant acidic Fibroblast Growth Factor (aFGF).
